

Abstract of the Disclosure

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy of the formula

A-D-B wherein

D is $-\text{NH}-\text{C}(\text{O})-\text{NH}-$

A is a substituted moiety of the formula: $-\text{L}-(\text{M}-\text{L}^1)_q$,

and

B is a substituted or unsubstituted up to tricyclic aryl or heteroaryl moiety with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen oxygen and sulfur.

L is a 5-6 membered cyclic structure bound directly to D,

L^1 comprises a substituted cyclic moiety having at least 5 members

M is a bridging group having at least one atom and q is an integer of from 1-3.

SEARCHED INDEXED
SERIALIZED FILED

10